**Table 1.** Baseline characteristics of patients in the study group as a whole (overall) and in patients with complete, partial, or no remission or who received hormone and Tripterygium as therapy.

| **Characteristic** | **Overall (n=124)** | **Complete Remission (n=76)** | **Partial Remission (n=26)** | **No Remission (n=22)** |
| --- | --- | --- | --- | --- |
| Female, n(%) | 37(29.8%) | 31(40.8%)a,b | 3(11.5%) | 3(13.6%) |
| History of smoke, n(%) | 15(12.1%) | 9(11.8%) | 3(11.5%) | 3(13.6%) |
| History of drink n(%) | 5(4.03%) | 3(3.95%) | 0(0%) | 2(9.09%) |
| Hypertension n(%) | 25(20.2%) | 16(21.1%) | 5(19.2%) | 4(18.2%) |
| Diabetes n(%) | 8(6.45%) | 4(5.26%) | 1(3.85%) | 3(13.6%) |
| Hepatitis B, n(%) | 13(10.5%) | 8(10.5%) | 2(7.69%) | 3(13.6%) |
| History of hormone, n(%) | 41(33.1%) | 20(26.3%) | 10(38.5%) | 11(50%) |
| History of CTX, n(%) | 9(7.26%) | 3(3.95%) | 3(11.5%) | 3(13.6%) |
| History of CNI, n(%) | 15(12.1%) | 5(6.58%)b | 4(15.4%) | 6(27.3%) |
| History of MMC, n(%) | 7(5.65%) | 5(6.58%) | 2(7.69%) | 0(0%) |
| History of Leflunomide, n(%) | 2(1.61%) | 1(1.32%) | 0(0%) | 1(4.55%) |
| ACEI/ARB, n(%) | 24(19.4%) | 14(18.4%) | 4(15.4%) | 6(27.3%) |
| Age (yr) | 50(42.8-61) | 50(42.8-61) | 50(44-60.5) | 54(36.2-56.8) |
| Height (cm) | 165±8.15 | 164±8.91 | 166±6.6 | 165±7.12 |
| Body weight (kg) | 66±10.8 | 65.5±11.5 | 67±8.8 | 66.8±10.9 |
| NS course (m) | 7(4-12) | 6.5(4-12) | 8.5(5.25-13.5) | 7.5(5-12) |
| Serum creatinine (mg/dl) | 76(61.8-88.2) | 74(55.8-85.2)b | 75(67.2-101) | 80.5(73.2-114) |
| CystatinC (mg/L) | 1.13(0.938-1.38) | 1.06(0.928-1.25)b | 1.26(0.933-1.52) | 1.24(0.972-1.64) |
| UA (umol/L) | 421±117 | 428±120 | 421±102 | 393±126 |
| Cholesterol (mg/dl) | 7.8(6.52-9.1) | 7.64(6.19-8.47)b | 7.94(6.98-9.12) | 9.32(7.29-11.1) |
| Serum albumin (g/dl) | 23.4±6.46 | 24.9±6.11 | 23.1±6.66b | 18.6±5.11 |
| Glucosuria （mmol/24h） | 4.76(4.43-5.22) | 4.9(4.46-5.3) | 4.66(4.36-5.1) | 4.62(4.47-4.99) |
| proteinuria (g/24h) | 6.1(3.61-9.15) | 4.8(3.35-7.66)a,b | 7.7(4.64-10.7) | 6.96(4.85-10.8) |
| eGFR (ml/min per 1.73 m²) | 106±33.5 | 113±32.5b | 99.9±33 | 88.6±31.1 |

Variables expressed as mean ± SD are compared using one-way ANOVA. Variables expressed as median (IQR) are compared using the Kruskal–Wallis test. Categorical variables are expressed in percentages and compared using the chi-squared test.

a*p*<0.05 versus partial remission.

b*p*<0.05 versus no remission.